# EDGAR Filing Document

**Accession Number:** 0001520262
**File Stem:** 0000950170-25-099382
**Filing Date:** 2025-7
**Character Count:** 38385
**Document Hash:** 070378477ba485e825820aa72bf234af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-099382.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0000950170-25-099382

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 28

**CONFORMED PERIOD OF REPORT**: 20250729

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alkermes plc.
- **CENTRAL INDEX KEY:** 0001520262
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981007018
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35299
- **FILM NUMBER:** 251157507

**BUSINESS ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** 00000
- **BUSINESS PHONE:** 00-353-1-772-8000

**MAIL ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANTLER SCIENCE TWO PLC
- **DATE OF NAME CHANGE:** 20110804

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Antler Science Two Ltd
- **DATE OF NAME CHANGE:** 20110509

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM** 8-K

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported):** July 29, 2025

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| Ireland | 001-35299 | 98-1007018 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
| Connaught House**,** 1 Burlington Road | Connaught House**,** 1 Burlington Road | Connaught House**,** 1 Burlington Road |
| Dublin 4**,** Ireland D04 C5Y6 | Dublin 4**,** Ireland D04 C5Y6 | Dublin 4**,** Ireland D04 C5Y6 |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) |

---

**Registrant's telephone number, including area code: +** 353**-**1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which registered** |
| &nbsp;&nbsp;Ordinary shares, $0.01 par value | &nbsp;&nbsp;ALKS | &nbsp;&nbsp;Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.** 

On July 29, 2025, Alkermes plc (the "Company") announced financial results for the three and six months ended June 30, 2025. Copies of the related press release and the investor presentation to be displayed during the Company's conference call on July 29, 2025 discussing such financial results are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.** 

(d) Exhibits

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [<u>Press release issued by Alkermes plc on July 29, 2025 announcing financial results for the three and six months ended June 30, 2025.</u>](alks-ex99_1.htm) |
| 99.2 | [<u>Investor presentation to be displayed by Alkermes plc on July 29, 2025.</u>](alks-ex99_2.htm) |
| 104 | Cover page interactive data file (embedded within the Inline XBRL document). |

---

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ALKERMES PLC** | **ALKERMES PLC** |
| Date: July 29, 2025 | By: | /s/ Blair C. Jackson |
|  |  | Blair C. Jackson |
|  |  | Executive Vice President, Chief Operating Officer (Interim Principal Financial Officer) |

---

------

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| &nbsp;&nbsp;<u>Alkermes Contacts:</u> |  |
| &nbsp;&nbsp;For Investors: | &nbsp;&nbsp;Sandy Coombs +1 781 609 6377 |
| &nbsp;&nbsp;For Media:  | &nbsp;&nbsp;Katie Joyce +1 781 249 8927 |

---

**Alkermes plc Reports Second Quarter 2025 Financial Results** 

*— Second Quarter Revenues of $390.7 Million —*

*— GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 —*

*— Company Reiterates 2025 Financial Expectations —*

*— Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress —*

**DUBLIN, July 29, 2025 —** <u>Alkermes plc</u> (Nasdaq: ALKS) today reported financial results for the second quarter of 2025.

"Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive topline results from Vibrance-1, our phase 2 study of alixorexton (ALKS 2680) in narcolepsy type 1, were an important milestone in the development program and underscore the differentiated features of alixorexton. These data also highlight the potential of orexin 2 receptor agonists to transform the treatment of narcolepsy. As we prepare to initiate a global phase 3 program, we look forward to sharing detailed results from Vibrance-1 at the upcoming World Sleep Congress and topline results from our Vibrance-2 study in patients with narcolepsy type 2 this fall."

**<u>Key Financial Highlights</u>**

**Revenues**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Three Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Six Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Six Months Ended** <br>**June 30,** |
| &nbsp;&nbsp;*(In millions)*  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| &nbsp;&nbsp;Total Revenues | $&nbsp;&nbsp;390.7 | $&nbsp;&nbsp;399.1 | $&nbsp;&nbsp;697.2 | $&nbsp;&nbsp;749.5 |
| &nbsp;&nbsp;Total Proprietary Net Sales | $&nbsp;&nbsp;307.2 | $&nbsp;&nbsp;269.3 | $&nbsp;&nbsp;551.7 | $&nbsp;&nbsp;502.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; VIVITROL<sup>®</sup> | $&nbsp;&nbsp;121.7 | $&nbsp;&nbsp;111.9 | $&nbsp;&nbsp;222.7 | $&nbsp;&nbsp;209.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ARISTADA<sup>®</sup><sup>i</sup> | $&nbsp;&nbsp;101.3 | $&nbsp;&nbsp;86.0 | $&nbsp;&nbsp;174.8 | $&nbsp;&nbsp;164.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYBALVI<sup>®</sup> | $&nbsp;&nbsp;84.3 | $&nbsp;&nbsp;71.4 | $&nbsp;&nbsp;154.3 | $&nbsp;&nbsp;128.4 |

---

**Profitability** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Three Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Six Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Six Months Ended** <br>**June 30,** |
| &nbsp;&nbsp;*(In millions)*  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| &nbsp;&nbsp;GAAP Net Income From Continuing Operations | $&nbsp;&nbsp;87.1 | $&nbsp;&nbsp;94.7 | $&nbsp;&nbsp;109.6 | $&nbsp;&nbsp;133.6 |
| &nbsp;&nbsp;*GAAP Net Income (Loss) From Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(3.3)* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(5.4)* |
| &nbsp;&nbsp;GAAP Net Income  | $&nbsp;&nbsp;87.1 | $&nbsp;&nbsp;91.4 | $&nbsp;&nbsp;109.6 | $&nbsp;&nbsp;128.2 |
| &nbsp;&nbsp;EBITDA From Continuing Operations | $&nbsp;&nbsp;101.6 | $&nbsp;&nbsp;118.6 | $&nbsp;&nbsp;124.3 | $&nbsp;&nbsp;170.1 |
| &nbsp;&nbsp;*EBITDA From Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(3.9)* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(6.4)* |
| &nbsp;&nbsp;EBITDA | $&nbsp;&nbsp;101.6 | $&nbsp;&nbsp;114.7 | $&nbsp;&nbsp;124.3 | $&nbsp;&nbsp;163.7 |
| &nbsp;&nbsp;Adjusted EBITDA | $&nbsp;&nbsp;126.5 | $&nbsp;&nbsp;135.3 | $&nbsp;&nbsp;172.1 | $&nbsp;&nbsp;217.1 |

---

------

**<u>Revenue Highlights</u>**

**LYBALVI**

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter were $84.3 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues and total prescriptions for the quarter grew 18% and 22%, respectively, compared to the second quarter of 2024.

**ARISTADA**<sup>i</sup>

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter were $101.3 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter grew 18% compared to the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;•During the quarter, the company recorded ARISTADA revenue of approximately $11.0 million related to gross-to-net favorability, primarily driven by Medicaid utilization adjustments.

**VIVITROL**

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter were $121.7 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter grew 9% compared to the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;•During the quarter, the company recorded VIVITROL revenue of approximately $9.0 million related to gross-to-net favorability, primarily driven by Medicaid utilization adjustments.

**Manufacturing & Royalty Revenues**

&nbsp;&nbsp;&nbsp;&nbsp;•VUMERITY<sup>®</sup> manufacturing and royalty revenues for the quarter were $39.4 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Royalty revenues from XEPLION<sup>®</sup>, INVEGA TRINZA<sup>®</sup>/TREVICTA<sup>®</sup> and INVEGA HAFYERA<sup>®</sup>/BYANNLI<sup>®</sup> for the quarter were $30.3 million.

**<u>Key Operating Expenses</u>**

Please see Note 1 below for details regarding discontinued operations.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Three Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Six Months Ended** <br>**June 30,** | &nbsp;&nbsp;**Six Months Ended** <br>**June 30,** |
| &nbsp;&nbsp;*(In millions)*  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| &nbsp;&nbsp;R&D Expense – Continuing Operations | $&nbsp;&nbsp;77.4 | $&nbsp;&nbsp;59.6 | $&nbsp;&nbsp;149.2 | $&nbsp;&nbsp;127.3 |
| &nbsp;&nbsp;*R&D Expense – Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*3.9* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*6.4* |
| &nbsp;&nbsp;SG&A Expense – Continuing Operations | $&nbsp;&nbsp;170.8 | $&nbsp;&nbsp;168.1 | $&nbsp;&nbsp;342.6 | $&nbsp;&nbsp;347.9 |
| &nbsp;&nbsp;*SG&A Expense – Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;— | $&nbsp;&nbsp;— | $&nbsp;&nbsp;— |

---

**<u>Balance Sheet</u>**

At June 30, 2025, the company recorded cash, cash equivalents and total investments of $1.05 billion, compared to $916.2 million at March 31, 2025.

**<u>Financial Expectations for 2025</u>**

Alkermes reiterates its financial expectations for 2025, as set forth in its press release dated Feb. 12, 2025.

**<u>Notes and Explanations</u>**

1. The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, *Discontinued Operations*. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three and six months ended June 30, 2024.

------

**<u>Conference Call</u>**

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.

**<u>About Alkermes plc</u>**

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

**<u>Non-GAAP Financial Measures</u>**

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense in addition to the components of EBITDA from earnings.

The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company's liquidity.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

**<u>Note Regarding Forward-Looking Statements</u>**

Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects; and the company's expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, alixorexton (formerly referred to as ALKS 2680). The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations; clinical development activities may not be initiated or completed on expected timelines or at all; the results of the company's development activities may not be positive, or predictive of future results

------

from such activities, results of future development activities or real-world results; the company's products or product candidates could be shown to be ineffective or unsafe; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may not agree with the company's regulatory approval strategies or may make adverse decisions regarding the company's products; potential changes in the cost, scope and duration of the company development programs; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company's products or products using the company's proprietary technologies; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

VIVITROL<sup>®</sup> is a registered trademark of Alkermes, Inc.; ARISTADA<sup>®</sup>, ARISTADA INITIO<sup>®</sup> and LYBALVI<sup>®</sup> are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI<sup>®</sup>, INVEGA HAFYERA<sup>®</sup>, INVEGA TRINZA<sup>®</sup>, TREVICTA<sup>®</sup> and XEPLION<sup>®</sup> are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY<sup>®</sup> is a registered trademark of Biogen MA Inc., used by Alkermes under license.

(tables follow)

<sup>i</sup> The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO<sup>®</sup>, unless the context indicates otherwise.

------

---

| | | |
|:---|:---|:---|
| **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** |
| **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** |
| **Condensed Consolidated Statements of Operations - GAAP** | **Three Months Ended** | **Three Months Ended** |
| **(In thousands, except per share data)** | **June 30, 2025** | **June 30, 2024** |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product sales, net | $307235 | $269273 |
| &nbsp;&nbsp;&nbsp;&nbsp;Manufacturing and royalty revenues | 83422 | 129858 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Revenues | 390657 | 399131 |
| Expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods manufactured and sold | 49460 | 61472 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 77370 | 59649 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 170849 | 168113 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets |  | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Expenses | 297679 | 289248 |
| Operating Income | 92978 | 109883 |
| Other Income, net: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 11090 | 10735 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  | (5952) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 771 | 2053 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Income, net | 11861 | 6836 |
| Income Before Income Taxes | 104839 | 116719 |
| Income Tax Provision | 17741 | 22061 |
| **Net Income From Continuing Operations** | 87098 | 94658 |
| **Loss From Discontinued Operations — Net of Tax** |  | (3300) |
| **Net Income — GAAP** | $87098 | $91358 |
| **GAAP Earnings Per Ordinary Share - Basic:** |  |  |
| &nbsp;&nbsp;From continuing operations | $0.53 | $0.56 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.02) |
| &nbsp;&nbsp;From net income | $0.53 | $0.54 |
| **GAAP Earnings Per Ordinary Share - Diluted:** |  |  |
| &nbsp;&nbsp;From continuing operations | $0.52 | $0.55 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.02) |
| &nbsp;&nbsp;From net income | $0.52 | $0.53 |
| **Weighted Average Number of Ordinary Shares Outstanding:** |  |  |
| &nbsp;&nbsp;Basic | 164959 | 168321 |
| &nbsp;&nbsp;Diluted | 168357 | 170977 |
| An itemized reconciliation between net income from continuing operations on a GAAP basis and Adjusted EBITDA is as follows: |  |  |
| **Net Income from Continuing Operations** | $87098 | $94658 |
| Adjustments: |  |  |
| &nbsp;&nbsp;Depreciation and amortization expense | 7818 | 6658 |
| &nbsp;&nbsp;Interest income | (11090) | (10735) |
| &nbsp;&nbsp;Interest expense |  | 5952 |
| &nbsp;&nbsp;Income tax provision | 17741 | 22061 |
| **EBITDA from Continuing Operations** | 101567 | 118594 |
| **EBITDA from Discontinued Operations** |  | (3913) |
| **EBITDA** | 101567 | 114681 |
| &nbsp;&nbsp;Share-based compensation | 24966 | 20601 |
| **Adjusted EBITDA** | $126533 | $135282 |

---

------

---

| | | |
|:---|:---|:---|
| **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** |
| **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** |
| **Condensed Consolidated Statements of Operations - GAAP** | **Six Months Ended** | **Six Months Ended** |
| **(In thousands, except per share data)** | **June 30, 2025** | **June 30, 2024** |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product sales, net | $551728 | $502809 |
| &nbsp;&nbsp;&nbsp;&nbsp;Manufacturing and royalty revenues | 145439 | 246691 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development revenue |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Revenues | 697167 | 749503 |
| Expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods manufactured and sold | 98657 | 120116 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 149187 | 127260 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 342553 | 347862 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets |  | 1073 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Expenses | 590397 | 596311 |
| Operating Income | 106770 | 153192 |
| Other Income, net: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 21231 | 20134 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  | (11930) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 2327 | 2235 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Income, net | 23558 | 10439 |
| Income Before Income Taxes | 130328 | 163631 |
| Income Tax Provision | 20766 | 30025 |
| **Net Income From Continuing Operations** | 109562 | 133606 |
| **Loss From Discontinued Operations — Net of Tax** |  | (5420) |
| **Net Income — GAAP** | $109562 | $128186 |
| **GAAP Earnings Per Ordinary Share - Basic:** |  |  |
| &nbsp;&nbsp;From continuing operations | $0.67 | $0.79 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.03) |
| &nbsp;&nbsp;From net income | $0.67 | $0.76 |
| **GAAP Earnings Per Ordinary Share - Diluted:** |  |  |
| &nbsp;&nbsp;From continuing operations | $0.65 | $0.78 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.03) |
| &nbsp;&nbsp;From net income | $0.65 | $0.75 |
| **Weighted Average Number of Ordinary Shares Outstanding:** |  |  |
| &nbsp;&nbsp;Basic | 164188 | 168152 |
| &nbsp;&nbsp;Diluted | 168470 | 171960 |
| An itemized reconciliation between net income from continuing operations on a GAAP basis and Adjusted EBITDA is as follows: |  |  |
| **Net Income from Continuing Operations** | $109562 | $133606 |
| Adjustments: |  |  |
| &nbsp;&nbsp;Depreciation and amortization expense | 15239 | 14714 |
| &nbsp;&nbsp;Interest income | (21231) | (20134) |
| &nbsp;&nbsp;Interest expense |  | 11930 |
| &nbsp;&nbsp;Income tax provision | 20766 | 30025 |
| **EBITDA from Continuing Operations** | 124336 | 170141 |
| **EBITDA from Discontinued Operations** |  | (6429) |
| **EBITDA** | 124336 | 163712 |
| &nbsp;&nbsp;Share-based compensation | 47776 | 53356 |
| **Adjusted EBITDA** | $172112 | $217068 |

---

------

---

| | | |
|:---|:---|:---|
| **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** |
| **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** |
| **Condensed Consolidated Balance Sheets** | **June 30,** | **December 31,** |
| **(In thousands)** | **2025** | **2024** |
| Cash, cash equivalents and total investments | $1054008 | $824816 |
| Receivables | 354906 | 389733 |
| Inventory | 191924 | 182887 |
| Contract assets | 1424 | 4990 |
| Prepaid expenses and other current assets | 71295 | 86077 |
| Property, plant and equipment, net | 239399 | 227564 |
| Intangible assets, net and goodwill | 83880 | 83917 |
| Deferred tax assets | 155533 | 154835 |
| Other assets | 100440 | 100748 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets** | $2252809 | $2055567 |
| Accrued sales discounts, allowances and reserves | $253173 | $272452 |
| Other current liabilities | 252789 | 192747 |
| Other long-term liabilities | 122263 | 125391 |
| Total shareholders' equity | 1624584 | 1464977 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Liabilities and Shareholders' Equity** | $2252809 | $2055567 |
| Ordinary shares outstanding (in thousands) | 165055 | 162177 |
| This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which the company intends to file in July 2025. | This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which the company intends to file in July 2025. | This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which the company intends to file in July 2025. |

---

------

## Exhibit 99.2

![Slide 1](alks-ex99_2s1.jpg)

Second Quarter 2025Financial Results & Business Update July 29, 2025 Exhibit 99.2

------

![Slide 2](alks-ex99_2s2.jpg)

Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans or prospects, including its expected revenue and profitability. The Company cautions that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks, assumptions and uncertainties. These risks, assumptions and uncertainties include, among others: whether the Company is able to achieve its financial expectations; the Company's commercial activities may not result in the benefits that the Company anticipates; clinical development activities may not be initiated or completed on expected timelines or at all; potential changes in the cost, scope, design or duration of the Company's development activities; the unfavorable outcome of arbitration, litigation, including so-called "Paragraph IV" litigation, or other proceedings or other disputes related to the Company's products or products using the Company's proprietary technologies; the U.S. Food and Drug Administration or other regulatory authorities may make adverse decisions regarding the Company's products; the Company and its licensees may not be able to continue to successfully commercialize their products or support growth of such products; there may be a reduction in payment rate or reimbursement for the Company's products or an increase in the Company's financial obligations to government payers; the Company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks, assumptions and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and in subsequent filings made by the Company with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov, and on the Company's website at www.alkermes.com in the 'Investors – SEC Filings' section. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation. Non-GAAP Financial Measures: This presentation includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. ("GAAP"), including EBITDA (earnings before interest, taxes, depreciation and amortization) and Adjusted EBITDA, which excludes from earnings share-based compensation expense in addition to the components of EBITDA. The Company provides these non-GAAP financial measures of the Company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures, to the extent reasonably determinable, can be found in the Appendix of this presentation. Note Regarding Trademarks: The Company and its affiliates are the owners of various U.S. federal trademark registrations (®) and other trademarks (TM), including ARISTADA®, ARISTADA INITIO® , LYBALVI® and VIVITROL®. INVEGA SUSTENNA® is a registered trademark of Johnson & Johnson or its affiliated companies. Any other trademarks referred to in this presentation are the property of their respective owners. Appearances of such other trademarks herein should not be construed as any indicator that their respective owners will not assert their rights thereto.

------

![Slide 3](alks-ex99_2s3.jpg)

Q2 2025 Financial and Operational Performance

------

![Slide 4](alks-ex99_2s4.jpg)

In millions Q2 2025 Financial Results Summary Total Revenue In millions GAAP Net Income GAAP Earnings Per Share Diluted Q2 2025 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024.

------

![Slide 5](alks-ex99_2s5.jpg)

In millions Q2 2025 Profitability GAAP Net Income From Continuing Operations In millions Adjusted EBITDA\* EBITDA\* From Continuing Operations In millions EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes from earnings share-based compensation expense in addition to the components of EBITDA.\*Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the Appendix of this presentation. Q2 2025 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024.

------

![Slide 6](alks-ex99_2s6.jpg)

Q2 2025 Revenue Summary In millions Q2'25 Q2'24 Total Proprietary Net Sales $307.2 $269.3 VIVITROL® $121.7 $111.9 ARISTADA®\* $101.3 $86.0 LYBALVI® $84.3 $71.4 Manufacturing & Royalty Revenue $83.4 $129.9 Total Revenue $390.7 $399.1 \*Inclusive of ARISTADA INITIO® \*\*Reflects expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024. \*\* \*\* Amounts in the table may not sum due to rounding.

------

![Slide 7](alks-ex99_2s7.jpg)

Alkermes: 2025 Financial Expectations\* \*These expectations were initially provided by the Company on Feb. 12, 2025, are reiterated by the Company on July 29, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. ‡Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the Appendix of this presentation. i Inclusive of ARISTADA INITIO® (in millions) Financial Expectations for Year Ending Dec. 31, 2025 Total Revenues $1,340 – $1,430 COGS $185 – $205 R&D Expense $305 – $335 SG&A Expense $655 – $685 GAAP Net Income $175 – $205 EBITDA‡ $215 – $245 Adjusted EBITDA‡ $310 – $340 Effective Tax Rate ~17% Expected net sales of proprietary products: VIVITROL® net sales of $440M – $460M ARISTADA®i net sales of $335M – $355M LYBALVI® net sales of $320M – $340M EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes from earnings share-based compensation expense in addition to the components of EBITDA.

------

![Slide 8](alks-ex99_2s8.jpg)

Q2 2025 Commercial Review

------

![Slide 9](alks-ex99_2s9.jpg)

LYBALVI® Performance and Expectations \*These expectations were initially provided by the Company on Feb. 12, 2025, are reiterated by the Company on July 29, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. LYBALVI Quarterly Net Sales ($M) Q2'25 LYBALVI net sales of $84.3M reflects 18% growth compared to Q2'24 Q2'25 gross-to-net deductions: ~29% Outlook: FY'25 net sales expected to range from $320M – $340M\*

------

![Slide 10](alks-ex99_2s10.jpg)

ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales\* ($M) Q2'25 ARISTADA net sales were $101.3M Outlook: FY'25 net sales expected to range from $335M – $355M†\* \*Inclusive of ARISTADA INITIO®†These expectations were initially provided by the Company on Feb. 12, 2025, are reiterated by the Company on July 29, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations.

------

![Slide 11](alks-ex99_2s11.jpg)

VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) \*These expectations were initially provided by the Company on Feb. 12, 2025, are reiterated by the Company on July 29, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. Q2'25 VIVITROL net sales were $121.7M Outlook: FY'25 net sales expected to range from $440M – $460M\*

------

![Slide 12](alks-ex99_2s12.jpg)

Appendix

------

![Slide 13](alks-ex99_2s13.jpg)

Appendix: Amounts Included in Discontinued Operations (In thousands) Year Ended December 31, 2023 Three Months Ended June 30, 2024 Cost of goods manufactured and sold $-- Research and development 3,913 Selling, general and administrative --- Income tax benefit $(613) Loss from discontinued operations, net of tax $3,300

------

![Slide 14](alks-ex99_2s14.jpg)

Appendix: Financial Results GAAP to Non-GAAP Reconciliation (In millions) Three Months Ended June 30, 2025 Three Months Ended June 30, 2024 Net Income from Continuing Operations — GAAP $87.1 $94.7 Adjustments: Depreciation and amortization expense 7.8 6.7 Interest income (11.1) (10.7) Interest expense -- 6.0 Income tax provision 17.7 22.1 EBITDA from Continuing Operations 101.6 118.6 EBITDA from Discontinued Operations -- (3.9) EBITDA 101.6 114.7 Share-based compensation 25.0 20.6 Adjusted EBITDA $126.5 $135.3 Amounts in the table may not sum due to rounding.

------

![Slide 15](alks-ex99_2s15.jpg)

Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation Projected GAAP and non-GAAP measures in the table above reflect the mid-points within the Company's financial expectations ranges. (In millions) Year Ended December 31, 2023 Year Ending December 31, 2025 Projected Net Income — GAAP $190.0 Adjustments: Net interest income (30.0) Depreciation and amortization expense 30.0 Provision for income taxes 40.0 Projected EBTIDA $230.0 Shared-based compensation expense 95.0 Projected Adjusted EBITDA $325.0

------

![Slide 16](alks-ex99_2s16.jpg)

www.alkermes.com